|
NUDCD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.27770000532846E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.41240000028908E-07 |
| Normal-vs-Stage2 |
5.221800E-02 |
| Normal-vs-Stage3 |
2.13019999999453E-05 |
| Normal-vs-Stage4 |
6.42679999995899E-07 |
| Stage1-vs-Stage2 |
1.620990E-01 |
| Stage1-vs-Stage3 |
8.177200E-01 |
| Stage1-vs-Stage4 |
1.413220E-01 |
| Stage2-vs-Stage3 |
2.084200E-01 |
| Stage2-vs-Stage4 |
3.707800E-02 |
| Stage3-vs-Stage4 |
2.910600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.6690000038142E-08 |
| Normal-vs-AfricanAmerican |
4.197800E-03 |
| Normal-vs-Asian |
1.55432999999761E-05 |
| Caucasian-vs-AfricanAmerican |
9.646200E-01 |
| Caucasian-vs-Asian |
9.112400E-01 |
| AfricanAmerican-vs-Asian |
9.840600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.9737999995838E-07 |
| Normal-vs-Female |
2.72299999992676E-07 |
| Male-vs-Female |
3.372400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.14620000157828E-08 |
| Normal-vs-Age(41-60Yrs) |
1.6505199999961E-05 |
| Normal-vs-Age(61-80Yrs) |
4.0239000000053E-05 |
| Normal-vs-Age(81-100Yrs) |
2.311000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.901170E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.948800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.072000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.838800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.913600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.019000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.406300E-02 |
| Classical-VS-Follicular |
5.879600E-01 |
| Classical-VS-Other |
6.367400E-01 |
| Classical-VS-Normal |
1.75619999998045E-06 |
| Tall-VS-Follicular |
4.461700E-02 |
| Tall-VS-Other |
6.473400E-01 |
| Tall-VS-Normal |
9.33459999963304E-07 |
| Follicular-VS-Other |
6.073200E-01 |
| Follicular-VS-Normal |
4.636900E-03 |
| Other-VS-Normal |
1.629560E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.15839999999834E-05 |
| Normal-vs-N1 |
2.06720000006655E-07 |
| N0-vs-N1 |
2.588100E-02 |
|
|
